Viking Therapeutics starts Phase 3 trials for oral obesity drug VK2735
Tweet Send to a Friend
Viking Therapeutics, Inc. (NASDAQ: VKTX) has initiated two Phase 3 clinical trials, SUNRISE-1 and SUNRISE-2, to evaluate an oral formulation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




